| P50 | author | David Meyronet | Q79383683 |
| P2093 | author name string | Jérôme Honnorat | |
| | François Ducray | |
| | Cristina Izquierdo | |
| | Marc Barritault | |
| | Bastien Joubert | |
| | Stéphanie Cartalat | |
| | Laure Thomas | |
| | Charlotte Bronnimann | |
| | Laura Delpech | |
| P2860 | cites work | Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial | Q29547224 |
| | A randomized trial of bevacizumab for newly diagnosed glioblastoma | Q30410163 |
| | Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma | Q33382596 |
| | End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria | Q33447142 |
| | Implications of bevacizumab discontinuation in adults with recurrent glioblastoma | Q33616621 |
| | Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab | Q34359710 |
| | Drug rechallenge and treatment beyond progression--implications for drug resistance. | Q35967416 |
| | Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients | Q36385285 |
| | Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial | Q37240846 |
| | Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma. | Q37606640 |
| | Clinical trial end points for high-grade glioma: the evolving landscape. | Q37839482 |
| | Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial | Q38921415 |
| | European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. | Q39291912 |
| | Impact of tapering and discontinuation of bevacizumab in patients with progressive glioblastoma | Q39597202 |
| | Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio | Q39896269 |
| | MMP2 and MMP9 as candidate biomarkers to monitor bevacizumab therapy in high-grade glioma | Q42364151 |
| | Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study | Q43121697 |
| | Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma | Q43164376 |
| | Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma | Q46796397 |
| | Lomustine and Bevacizumab in Progressive Glioblastoma | Q47399678 |
| | Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer. | Q47667903 |
| | MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial | Q48342416 |
| | Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial. | Q49112520 |
| | Characteristics of H3 K27M-mutant gliomas in adults. | Q53769248 |
| | Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma-Results of the REchallenge with SUnitinib in MEtastatic RCC (RESUME) Study. | Q53785436 |
| | [An evaluation of fatigue in patients with glioblastoma relapse treated with the combination of irinotecan-bevacizumab]. | Q55463162 |
| P433 | issue | 1 | |
| P921 | main subject | glioblastoma | Q282142 |
| | bevacizumab | Q413299 |
| P304 | page(s) | 141-145 | |
| P577 | publication date | 2018-01-31 | |
| P1433 | published in | Journal of Neuro-Oncology | Q15752119 |
| P1476 | title | Rechallenge with bevacizumab in patients with glioblastoma progressing off therapy | |
| P478 | volume | 138 | |